A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
• HL patients with relapse or progression. Prior checkpoint inhibitors will be allowed
• Patients with relapsed HL involving extranodal sites
• HL patients who are not regarded as a candidate for high-dose, conventional chemotherapy
• Age of enrollment: Minimum age 1 year. No maximum age, study will include anyone in the pediatric/adolescent center at MD Anderson (MDA)
• Eastern Cooperative Oncology Group (ECOG) performance status =\< 3 or Lansky performance status \>= 50
• Adequate renal function per age unless related to the disease
• Total bilirubin \< 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease
• Aspartate Aminotransferase (AST) \< 3 x ULN unless considered due to lymphoma involvement
• Provision of written informed consent or assent as per MD Anderson Cancer Center (MDACC) policy for study subjects
• Females must be surgically or biologically sterile or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment and each subsequent dose
• Women of childbearing potential must agree to use an adequate method of contraception during the study and until 4 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 1 month after the last treatment
• Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment